The efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome
10.3760/cma.j.issn.1008-6706.2013.05.013
- VernacularTitle:磺达肝癸钠治疗高龄急性冠脉综合征的疗效及安全性
- Author:
Xiang CHEN
;
Youming TUO
;
Shaohua CHEN
;
Dali SU
;
Pin Yü
;
Yixin LI
- Publication Type:Journal Article
- Keywords:
Liver of dibutyl sebacate with sodium sulfonated;
Low molecular weight heparin calcium;
Acute coronary syndrome;
Anticoagulant therapy
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(5):673-675
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome (ACS).Methods84 ACS patients over 70 years were randomly divided into the treatment and control groups.Two groups were treated on the basis of general,treatment 40 cases of liver of dibutyl sebacate with sodium sulfonated added 2.5 mg subcutaneous injection parumbilical,day 1,course 8 d ; control group 44 cases combined with low molecular weight heparin calcium 0.4 ml,2 times/day 1 time every 12 hours,according to body weight adjusted dose,Parumbilical shot in course of 8 days,observing the clinical effect of two groups during the treatment,as well as 4 weeks and bleeding during the treatment the incidence of cardiovascular events.Results The clinical effects of treatment and control groups was no significant difference (95％ and 91％,P ＞0.05) ; None of the two sets of death,myocardial infarction and recurrent malignant ventricular arrhythmia; none of the two sets of bleeding occurs,treatment of minor bleeding rates were significantly lower than those of control groups (7.5％ and 25％,P ＜ 0.05).Conclusion The study of dibutyl sebacate with sodium heparin and low molecular weight heparin calcium in the treatment of ACS are valid,but the former which significantly reduce the incidence of minor bleeding.Liver decanoic sulfonic sodium for acute coronary syndrome ACS)anticoagulation can not only effectively reduce cardiovascular events,but also significantly reduce bleeding risk,regardless of the patient's age,gender,renal function and risk stratification,especially for bleeding in high risk elderly patients with safe and clinical promotion.
